Corporate Market Update
Orchestra Biomed Holdings Inc. (OTC: OBIO) advanced 2.19 % during the 24‑hour trading window that closed at 02:50 PM Central Europe on Monday, 26 November 2026. At the close, one share of OBIO traded at approximately USD 5.52 on major exchanges. The company’s free float stands at 60.1 million shares, yielding a market capitalization of roughly USD 336 million. In the past 24 hours, a total of about USD 1.5 million worth of OBIO shares exchanged hands.
Since the end of October, OBIO’s price has declined by 6.05 %. The 200‑day simple moving average currently sits at USD 4.50, a level below which the stock has been trading for several weeks. The high of the last 52 weeks—USD 6.50—was reached on 10 January 2026, while the 52‑week low of USD 3.46 occurred on 30 January 2026.
Comparative Performance in the Same Period
| Ticker | 24‑hr Change | Current Price (USD) | Market Cap (USD mn) | Notes |
|---|---|---|---|---|
| ALTI (Alti Global) | –3.37 % | 2.54 | 399 | — |
| PCB (Pcb) | –0.49 % | 28.64 | 402.2 | P/E 9.91 |
| SPRY (Ars) | –6.71 % | 4.07 | 400.8 | — |
| OFIX (Orthofix Medical) | –1.8 % | 9.69 | 399.6 | — |
| CTEV (Claritev) | 0 % | 23.50 | 398.3 | — |
Pcb’s modest decline is offset by its strong earnings multiple, while Ars and Alti Global saw steeper losses, reflecting broader sector volatility. Orthofix Medical and Claritev maintained relative stability.
Context: Recent IPO Activity
The recent initial public offering of Dongshan Precision Manufacturing—a Shenzhen‑listed PCB and optical‑transceiver producer—offers a backdrop to OBIO’s performance. The Hong Kong IPO raised approximately HK$9.9 billion by selling 114 million shares at HK$86.80 each, a discount to the Shenzhen‑listed price after a decline from its June peak. The listing, slated to begin trading on 28 October, attracted cornerstone investors such as JPMorgan Asset Management and Alibaba Group. Dongshan’s role as a key supplier in the AI server market underscores the continued importance of chip‑board supply chains amid a cautiously optimistic market environment, characterized by rising bond yields and mixed results from recent first‑time listings in Hong Kong.
Company Focus
Orchestra Biomed Holdings operates as a holding company within the health‑care sector. Through its subsidiaries, it seeks to foster strategic collaborations with medical‑device manufacturers to accelerate the global commercialization of innovative products. The company’s website, www.orchestrabiomed.com , details its portfolio and partnership initiatives. As a Nasdaq‑listed entity, OBIO maintains a transparent regulatory framework and a dedicated investor relations program.
This report synthesizes current trading data and contextual market events to provide a comprehensive overview of Orchestra Biomed’s recent performance and its position relative to peers in the sector.
